\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Digital, Industry & Space EIC SME InstrumentIs your SME looking to embrace digital innovation? Connect with a supplier from the HUBCAP platform and receive tailormade support and services to co-create and experiment with CPS & MBD tools.
The HUBCAP initiative aim at upgrading the capacity of SMEs to leverage Model-Based Design (MBD) technology in Cyber Physical Systems (CPS) and ultimately deliver new products and services in multiple application domains. HUBCAP provides services and technical expertise and offers financial support for European SMEs to experiment in highly innovative, cross-border experiments.
At the moment the "experiment" call is open (until 2 Feb 2022). Eligible applications need to come from consortia of 2 SME's, where MBD CPS users/adopters will work with MBD CPS providers and experiment with MBD tools to implement these digital solutions in their products/services.
What your consortium will receive:
More information about the Experiment call can be found on https://www.hubcap.eu/open-calls
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
